BRAF and metastatic melanoma: Recently, the advent of BRAF inhibitors, immune checkpoint inhibitors (ICIs), and their application as combination or sequential therapies have revolutionized clinical practice, leading to significant increases in survival rates for patients when compared to those for older cytotoxic treatment strategies for metastatic melanoma [44].